Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy - Top-Institutions - MDSpire

Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy

  • By

  • Qin Ye

  • Meng Li

  • Ping Zhou

  • Shan Huang

  • Ke Xie

  • May 8, 2026

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Hematology
    • Oncology

  • #2

    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

    Key Differentiators

    • Hematology
    • Oncology

  • #3

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Hematology
    • Oncology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Hematology
    • Oncology

  • #5

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Hematology
    • Oncology

Original Source(s)

Severe immune-related autoimmune hemolytic anemia induced by pembrolizumab: a case report with novel immunosuppressive strategy

  • by Qin Ye, Meng Li, Ping Zhou, Shan Huang, Ke Xie

  • May 8, 2026

Related Content

Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

Predictors and surgical outcome of hemorrhagic metastatic brain malignancies

Engineering CAR T Cells to Resist Tumor Immune Suppression

CRISPR editing removes PGE2 receptors from therapeutic T cells, improving persistence and tumor control in preclinical models

  • March 9, 2026

  • 2 min